Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
#2PRI RANKED
Most Cited Paper
in Liver Disease Diagnosis and Treatment
18 Months Post-Publication
Class of 2026
“Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
tirzepatide · Steatohepatitis · Steatohepatitis · Liver fibrosis · glucose-dependent insulinotropic polypeptide receptor · GIP receptor agonist · GLP-1 receptor · GLP-1 receptor agonists · dual agonist · Fibrosis stage F2 · Fibrosis stage F3 · Steatohepatitis resolution · Liver fibrosis improvement · liver biopsy · Subcutaneous administration · dose-finding trial · 52-week treatment · gastrointestinal adverse events
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Liver Disease Diagnosis and Treatment Papers, Class of 2026. https://pri.pepkio.com/top-papers/liver-disease-diagnosis-and-treatment/2026. Accessed 2026-07-24. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459